Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Markus Axelsson
Observed names:
Axelsson M,
Axelsson, M.,
Axelsson, Markus,
M Axelsson,
M. Axelsson
Institutions:
Sahlgrenska University Hospital,
Region Västra Götaland,
University of Gothenburg
Observed institutions:
Sahlgrenska University Hospital,
Danderyds sjukhus,
Karolinska Institutet,
Region Västra Götaland,
UCL Queen Square Institute of Neurology,
University College London,
University of Gothenburg,
Umeå University
show all 8
ORCID:
0000-0003-2036-4007
Observed ORCID:
0000-0003-2036-4007
OpenAlex ID:
A5041446091
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis
2019
·
Claire Bridel
, Wessel N. van Wieringen
, et al.
·
JAMA Neurology
·
819
A multicentre validation study of the diagnostic value of plasma neurofilament light
2021
·
Nicholas J. Ashton
, Shorena Janelidze
, et al.
·
Nature Communications
·
590
PDF
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
2017
·
Lenka Novakova
, Henrik Zetterberg
, et al.
·
Neurology
·
443
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
2016
·
Jonatan Salzer
, Rasmus Svenningsson
, et al.
·
Neurology
·
369
PDF
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
2010
·
Martin Gunnarsson
, Clas Malmeström
, et al.
·
Annals of Neurology
·
355
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
2016
·
Peter Alping
, Thomas Frisell
, et al.
·
Annals of Neurology
·
235
PDF
Inflammation-related plasma and CSF biomarkers for multiple sclerosis
2020
·
Jesse Huang
, Mohsen Khademi
, et al.
·
Proceedings of the National Academy of Sciences
·
202
Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis
2010
·
M. Axelsson
, C. Malmeström
, et al.
·
Journal of Neurology
·
201
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
2022
·
Anders Svenningsson
, Thomas Frisell
, et al.
·
The Lancet Neurology
·
155
Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing‐remitting multiple sclerosis
2016
·
Lenka Novakova
, Markus Axelsson
, et al.
·
Journal of Neurochemistry
·
151
PDF
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
2013
·
Markus Axelsson
, Clas Malmeström
, et al.
·
Multiple Sclerosis Journal
·
132
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
2016
·
Lenka Novakova
, Markus Axelsson
, et al.
·
Multiple Sclerosis Journal
·
114
PDF
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone
2016
·
Annika Öhrfelt
, Markus Axelsson
, et al.
·
Multiple Sclerosis Journal
·
101
PDF
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis
2013
·
J. Kuhle
, C. Malmeström
, et al.
·
Acta Neurologica Scandinavica
·
90
MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS)
2013
·
Margareta Jernås
, Clas Malmeström
, et al.
·
BMC Immunology
·
88
PDF
YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis
2016
·
Joachim Burman
, Raili Raininko
, et al.
·
Journal of Neuroimmunology
·
81
PDF
Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society
2016
·
M. Vågberg
, M. Axelsson
, et al.
·
Acta Neurologica Scandinavica
·
76
PDF
CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment
2014
·
Clas Malmeström
, Markus Axelsson
, et al.
·
Journal of Neuroimmunology
·
67
Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A real‐world investigation
2021
·
Igal Rosenstein
, Sofia Rasch
, et al.
·
Journal of Neurochemistry
·
65
Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis
2009
·
N Mattsson
, M Axelsson
, et al.
·
Multiple Sclerosis Journal
·
61
Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long‐term outcome in patients with autoimmune encephalitis
2016
·
R. Constantinescu
, D. Krýsl
, et al.
·
European Journal of Neurology
·
58
PDF
Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers
2018
·
Lenka Novakova
, Markus Axelsson
, et al.
·
PLoS ONE
·
56
PDF
Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosis
2023
·
Igal Rosenstein
, Markus Axelsson
, et al.
·
Journal of Neurology
·
55
PDF
Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
2020
·
Christina Zhukovsky
, Sofia Sandgren
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
55
PDF
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis
2012
·
Kristin Augutis
, Markus Axelsson
, et al.
·
Multiple Sclerosis Journal
·
49
Show more works
View as search
Works count:
111
Citation count:
5,774
H-index:
32
I10-index:
57
Year
Topic
Type